Mountain Pacific Investment Advisers Inc. ID maintained its position in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent filing with the SEC. The firm owned 2,400 shares of the medical technology company’s stock at the end of the second quarter. Mountain Pacific Investment Advisers Inc. ID’s holdings in Stryker Corporation were worth $333,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in SYK. Bollard Group LLC increased its position in shares of Stryker Corporation by 0.4% in the first quarter. Bollard Group LLC now owns 829 shares of the medical technology company’s stock valued at $109,000 after buying an additional 3 shares during the last quarter. Assetmark Inc. increased its position in shares of Stryker Corporation by 0.3% in the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock valued at $168,000 after buying an additional 4 shares during the last quarter. Blue Chip Partners Inc. increased its position in shares of Stryker Corporation by 0.3% in the first quarter. Blue Chip Partners Inc. now owns 1,775 shares of the medical technology company’s stock valued at $234,000 after buying an additional 6 shares during the last quarter. Guardian Life Insurance Co. of America increased its position in shares of Stryker Corporation by 0.8% in the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock valued at $158,000 after buying an additional 9 shares during the last quarter. Finally, Baystate Wealth Management LLC increased its position in shares of Stryker Corporation by 2.1% in the first quarter. Baystate Wealth Management LLC now owns 1,066 shares of the medical technology company’s stock valued at $139,000 after buying an additional 22 shares during the last quarter. Institutional investors and hedge funds own 74.25% of the company’s stock.
Shares of Stryker Corporation (NYSE:SYK) opened at 146.19 on Friday. The company has a 50 day moving average price of $142.05 and a 200-day moving average price of $132.85. The stock has a market cap of $54.64 billion, a price-to-earnings ratio of 32.85 and a beta of 0.79. Stryker Corporation has a one year low of $106.48 and a one year high of $148.15.
Stryker Corporation (NYSE:SYK) last posted its earnings results on Tuesday, April 25th. The medical technology company reported $1.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.43 by $0.05. Stryker Corporation had a net margin of 14.33% and a return on equity of 24.26%. The firm had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $2.90 billion. During the same quarter last year, the firm earned $1.24 EPS. The firm’s revenue for the quarter was up 18.4% on a year-over-year basis. Equities analysts predict that Stryker Corporation will post $6.43 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, July 31st. Shareholders of record on Friday, June 30th will be paid a $0.425 dividend. The ex-dividend date of this dividend is Wednesday, June 28th. This represents a $1.70 annualized dividend and a dividend yield of 1.16%. Stryker Corporation’s dividend payout ratio (DPR) is 38.20%.
Several brokerages have recently commented on SYK. BMO Capital Markets restated a “hold” rating and issued a $125.00 price objective on shares of Stryker Corporation in a research report on Tuesday, April 11th. Oppenheimer Holdings, Inc. set a $135.00 target price on Stryker Corporation and gave the stock a “hold” rating in a report on Saturday, April 8th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $132.00 target price on shares of Stryker Corporation in a report on Thursday, April 13th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $148.00 target price on shares of Stryker Corporation in a report on Monday, April 17th. Finally, Barclays PLC reaffirmed a “sell” rating and issued a $133.00 target price on shares of Stryker Corporation in a report on Thursday, April 27th. Three analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $140.13.
In other news, insider David Floyd sold 19,305 shares of Stryker Corporation stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total transaction of $2,790,730.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Timothy J. Scannell sold 13,322 shares of Stryker Corporation stock in a transaction on Tuesday, May 2nd. The stock was sold at an average price of $135.89, for a total transaction of $1,810,326.58. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,008 shares of company stock valued at $5,669,088. Insiders own 7.40% of the company’s stock.
About Stryker Corporation
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
